OPC Pharmaceutical JSC (HOSE:OPC)
23,700
+100 (0.42%)
At close: Apr 2, 2025
OPC Pharmaceutical JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Revenue | 968,576 | 1,004,887 | 1,171,614 | 1,123,728 | 965,591 | Upgrade
|
Revenue Growth (YoY) | -3.61% | -14.23% | 4.26% | 16.38% | -2.40% | Upgrade
|
Cost of Revenue | 522,458 | 526,456 | 637,906 | 643,499 | 572,130 | Upgrade
|
Gross Profit | 446,118 | 478,431 | 533,708 | 480,229 | 393,460 | Upgrade
|
Selling, General & Admin | 311,717 | 332,311 | 355,073 | 313,516 | 257,049 | Upgrade
|
Operating Expenses | 311,717 | 332,311 | 355,073 | 313,516 | 257,049 | Upgrade
|
Operating Income | 134,401 | 146,120 | 178,636 | 166,713 | 136,411 | Upgrade
|
Interest Expense | - | -334.55 | -925.2 | -4,819 | -5,490 | Upgrade
|
Interest & Investment Income | 8,335 | 15,854 | 7,813 | 3,707 | 4,391 | Upgrade
|
Earnings From Equity Investments | 1,535 | 838.45 | 797.74 | 172.88 | 1,877 | Upgrade
|
Currency Exchange Gain (Loss) | 448.73 | 555.41 | 279.37 | 360.84 | 622.41 | Upgrade
|
Other Non Operating Income (Expenses) | -7,627 | -7,710 | -6,677 | -6,894 | -5,034 | Upgrade
|
EBT Excluding Unusual Items | 137,093 | 155,323 | 179,924 | 159,241 | 132,778 | Upgrade
|
Pretax Income | 137,093 | 155,323 | 179,924 | 159,241 | 132,778 | Upgrade
|
Income Tax Expense | 27,666 | 33,004 | 37,530 | 35,878 | 29,871 | Upgrade
|
Earnings From Continuing Operations | 109,428 | 122,319 | 142,394 | 123,363 | 102,907 | Upgrade
|
Minority Interest in Earnings | -2,394 | -84.74 | -266.22 | 3,014 | 2,884 | Upgrade
|
Net Income | 107,034 | 122,234 | 142,128 | 126,377 | 105,791 | Upgrade
|
Preferred Dividends & Other Adjustments | 16,055 | 17,543 | 14,010 | 13,416 | 10,993 | Upgrade
|
Net Income to Common | 90,978 | 104,691 | 128,118 | 112,961 | 94,798 | Upgrade
|
Net Income Growth | -12.44% | -14.00% | 12.46% | 19.46% | 4.81% | Upgrade
|
Shares Outstanding (Basic) | 64 | 64 | 64 | 64 | 64 | Upgrade
|
Shares Outstanding (Diluted) | 64 | 64 | 64 | 64 | 64 | Upgrade
|
Shares Change (YoY) | - | - | - | -0.00% | - | Upgrade
|
EPS (Basic) | 1420.41 | 1634.49 | 2000.25 | 1763.61 | 1480.03 | Upgrade
|
EPS (Diluted) | 1420.00 | 1634.00 | 2000.00 | 1763.61 | 1480.03 | Upgrade
|
EPS Growth | -13.10% | -18.30% | 13.40% | 19.16% | 4.88% | Upgrade
|
Free Cash Flow | 18,297 | 243,317 | 28,688 | 181,809 | 93,340 | Upgrade
|
Free Cash Flow Per Share | 285.67 | 3798.80 | 447.90 | 2838.51 | 1457.27 | Upgrade
|
Dividend Per Share | - | 1500.000 | 1500.000 | - | 1244.813 | Upgrade
|
Gross Margin | 46.06% | 47.61% | 45.55% | 42.73% | 40.75% | Upgrade
|
Operating Margin | 13.88% | 14.54% | 15.25% | 14.84% | 14.13% | Upgrade
|
Profit Margin | 9.39% | 10.42% | 10.94% | 10.05% | 9.82% | Upgrade
|
Free Cash Flow Margin | 1.89% | 24.21% | 2.45% | 16.18% | 9.67% | Upgrade
|
EBITDA | 156,619 | 169,015 | 201,454 | 189,215 | 158,152 | Upgrade
|
EBITDA Margin | 16.17% | 16.82% | 17.20% | 16.84% | 16.38% | Upgrade
|
D&A For EBITDA | 22,218 | 22,895 | 22,819 | 22,502 | 21,740 | Upgrade
|
EBIT | 134,401 | 146,120 | 178,636 | 166,713 | 136,411 | Upgrade
|
EBIT Margin | 13.88% | 14.54% | 15.25% | 14.84% | 14.13% | Upgrade
|
Effective Tax Rate | 20.18% | 21.25% | 20.86% | 22.53% | 22.50% | Upgrade
|
Revenue as Reported | 968,576 | 1,004,887 | 1,171,614 | 1,123,728 | 965,591 | Upgrade
|
Advertising Expenses | 43,302 | 51,343 | 48,858 | 40,148 | 17,880 | Upgrade
|
Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.